Ansun Biopharma, Inc.
- UEI
- U654K98LEUP1
- CAGE
- 414L7
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- ansunbiopharma.com
- Founded
- 2003
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| R & d-drug dependency-a RES/expl DEV | NIAID DEA OA Acquisitions (NIH) | $55,802,128 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Proof-of-principle studies of DAS181 for parainfluenza virus infection | National Institutes of Health | $299,998 | |
| Development of fludase as an anti-influenza agent | National Institutes of Health | $1,015,668 | |
| Development of fludase for prevention of influenza | National Institutes of Health | $2,000,000 |
Quick answers
Is Ansun Biopharma, Inc. registered in SAM.gov?
Ansun Biopharma, Inc.'s SAM.gov registration expired on November 26, 2019.
What is Ansun Biopharma, Inc.'s most recent federal award?
Ansun Biopharma, Inc.'s most recent federal grant award is Proof-of-principle studies of DAS181 for parainfluenza virus infection (R43AI085893), from National Institutes of Health, on March 1, 2010.
On GovTribe
See Ansun Biopharma, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors